Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Bee pathogen transmission dynamics: deposition, persistence and acquisition on flowers.

Figueroa LL, Blinder M, Grincavitch C, Jelinek A, Mann EK, Merva LA, Metz LE, Zhao AY, Irwin RE, McArt SH, Adler LS.

Proc Biol Sci. 2019 May 29;286(1903):20190603. doi: 10.1098/rspb.2019.0603. Epub 2019 May 29.

PMID:
31138075
2.

Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia.

Fields ME, Guilliams KP, Ragan D, Binkley MM, Mirro A, Fellah S, Hulbert ML, Blinder M, Eldeniz C, Vo K, Shimony JS, Chen Y, McKinstry RC, An H, Lee JM, Ford AL.

Blood. 2019 May 30;133(22):2436-2444. doi: 10.1182/blood-2018-09-876318. Epub 2019 Mar 11.

PMID:
30858231
3.

Plasmapheresis for Management of Antiphospholipid Syndrome in the Neurosurgical Patient.

Arias EJ, Bruck B, Vellimana AK, Eby C, Reynolds MR, Blinder MA, Zipfel GJ.

Oper Neurosurg (Hagerstown). 2019 Apr 1;16(4):E124-E129. doi: 10.1093/ons/opy135.

PMID:
29800263
4.

Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.

Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.

Curr Med Res Opin. 2018 Nov;34(11):1959-1966. doi: 10.1080/03007995.2018.1470500. Epub 2018 Jun 4. Erratum in: Curr Med Res Opin. 2019 Mar;35(3):559.

PMID:
29701080
5.

Acute graft-versus-host disease following lung transplantation in a patient with a novel TERT mutation.

Brestoff JR, Vessoni AT, Brenner KA, Uy GL, DiPersio JF, Blinder M, Witt CA, Byers DE, Hachem RR, Truclock EP, Early DS, Anadkat MJ, Musiek A, Javidan-Nejad C, Balfe DM, Rosman IS, Liu C, Zhang L, Despotis GJ, Ruzinova MB, Sehn JK, Amarillo I, Heusel JW, Swat W, Kim BS, Wartman LD, Yusen RD, Batista LFZ.

Thorax. 2018 May;73(5):489-492. doi: 10.1136/thoraxjnl-2017-211121. Epub 2018 Jan 30.

6.

Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.

Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators.

N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066.

7.

Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review.

Rashidi A, Blinder MA.

J Clin Pharm Ther. 2016 Oct;41(5):453-8. doi: 10.1111/jcpt.12421. Epub 2016 Jul 8.

PMID:
27387045
8.

Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.

Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

J Emerg Med. 2015 Oct;49(4):513-522.e1. doi: 10.1016/j.jemermed.2014.12.080. Epub 2015 Apr 21.

PMID:
25910824
9.

Crime, punishment, and the American criminal justice system.

Blinder M.

J Am Acad Psychiatry Law. 2015 Mar;43(1):2-4. No abstract available.

PMID:
25770273
10.

Exertional sickling: questions and controversy.

Blinder MA, Russel S.

Hematol Rep. 2014 Dec 3;6(4):5502. doi: 10.4081/hr.2014.5502. eCollection 2014 Nov 19.

11.

Systemic effects of subcutaneous heparin use in otolaryngology patients.

Blank SJ, Grindler DJ, Zerega J, Blinder M, Nussenbaum B.

Otolaryngol Head Neck Surg. 2014 Dec;151(6):967-71. doi: 10.1177/0194599814552055. Epub 2014 Sep 25.

PMID:
25257903
12.

Successful orthotopic liver transplantation in an adult patient with sickle cell disease and review of the literature.

Blinder MA, Geng B, Lisker-Melman M, Crippin JS, Korenblat K, Chapman W, Shenoy S, Field JJ.

Hematol Rep. 2013 May 2;5(1):1-4. doi: 10.4081/hr.2013.e1. Print 2013 Jan 25.

13.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.

Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Pediatr Blood Cancer. 2013 May;60(5):828-35. doi: 10.1002/pbc.24459. Epub 2013 Jan 17.

PMID:
23335275
14.

Cancer- and chemotherapy-induced anemia.

Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd.

J Natl Compr Canc Netw. 2012 May;10(5):628-53.

PMID:
22570293
15.

Abnormalities in cardiac structure and function in adults with sickle cell disease are not associated with pulmonary hypertension.

Knight-Perry JE, de Las Fuentes L, Waggoner AD, Hoffmann RG, Blinder MA, Dávila-Román VG, Field JJ.

J Am Soc Echocardiogr. 2011 Nov;24(11):1285-90. doi: 10.1016/j.echo.2011.07.009. Epub 2011 Aug 27.

16.

Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease.

Cohen RT, Madadi A, Blinder MA, DeBaun MR, Strunk RC, Field JJ.

Am J Hematol. 2011 Sep;86(9):756-61. doi: 10.1002/ajh.22098. Epub 2011 Aug 2.

17.

Smoking is associated with an increased risk of acute chest syndrome and pain among adults with sickle cell disease.

Cohen RT, DeBaun MR, Blinder MA, Strunk RC, Field JJ.

Blood. 2010 May 6;115(18):3852-4. doi: 10.1182/blood-2010-01-265819. No abstract available.

18.

Commentary.

Blinder MA.

Clin Chem. 2010 Jan;56(1):19-20. doi: 10.1373/clinchem.2009.137091. No abstract available.

19.

Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature.

Ling HT, Field JJ, Blinder MA.

Am J Hematol. 2009 Jul;84(7):418-21. doi: 10.1002/ajh.21439. Review.

20.

Urinary cysteinyl leukotriene E4 significantly increases during pain in children and adults with sickle cell disease.

Field JJ, Strunk RC, Knight-Perry JE, Blinder MA, Townsend RR, DeBaun MR.

Am J Hematol. 2009 Apr;84(4):231-3. doi: 10.1002/ajh.21370.

21.

Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease.

Field JJ, Krings J, White NL, Yan Y, Blinder MA, Strunk RC, Debaun MR.

Am J Hematol. 2009 Mar;84(3):158-60. doi: 10.1002/ajh.21348.

22.

Reticulocyte hemoglobin content.

Mast AE, Blinder MA, Dietzen DJ.

Am J Hematol. 2008 Apr;83(4):307-10.

23.

Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome.

Fong T, Vij R, Vijayan A, DiPersio J, Blinder M.

Haematologica. 2007 Oct;92(10):1429-30.

24.

Laparoscopic versus open abdominal surgery in children with sickle cell disease is associated with a shorter hospital stay.

Goers T, Panepinto J, Debaun M, Blinder M, Foglia R, Oldham KT, Field JJ.

Pediatr Blood Cancer. 2008 Mar;50(3):603-6.

PMID:
17480009
25.

(18)F-FDG-PET-facilitated diagnosis of lymphoma presenting with fever of unknown origin and cold agglutination.

Krem MM, Pan L, Blinder MA.

Leuk Lymphoma. 2007 Mar;48(3):619-22. No abstract available.

PMID:
17454608
26.

Shoulder arthroplasty in sickle cell patients with humeral head avascular necrosis.

Lau MW, Blinder MA, Williams K, Galatz LM.

J Shoulder Elbow Surg. 2007 Mar-Apr;16(2):129-34. Epub 2007 Jan 31.

PMID:
17275355
27.
28.

Immunosuppressive therapy for acute porphyria: safety and efficacy in a patient with bone marrow failure.

Field JJ, Giannone L, Bessler M, Blinder MA.

Pharmacotherapy. 2006 Nov;26(11):1662-6.

PMID:
17064214
29.

Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases.

Deitcher SR, Ngengwe R, Kaplan R, Liebman H, Kaplan K, Blinder M.

Clin Adv Hematol Oncol. 2004 Jun;2(6):382-4; discussion 384-6. No abstract available.

PMID:
16163209
30.

Suicide, psychiatric malpractice, and the bell curve.

Blinder M.

J Am Acad Psychiatry Law. 2004;32(3):319-23.

PMID:
15515923
31.

Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain.

Kravtsov DV, Wu W, Meijers JC, Sun MF, Blinder MA, Dang TP, Wang H, Gailani D.

Blood. 2004 Jul 1;104(1):128-34. Epub 2004 Mar 16.

32.

Hemostatic complications associated with paraproteinemias.

Eby C, Blinder M.

Curr Hematol Rep. 2003 Sep;2(5):388-94. Review.

PMID:
12932310
33.

Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.

Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA.

Ann Intern Med. 2003 Jan 21;138(2):105-8.

PMID:
12529092
34.

Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency.

Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ.

Blood. 2002 Feb 15;99(4):1489-91.

35.

Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.

Tabrizi AR, McGrath SD, Blinder MA, Buchman TG, Zehnbauer BA, Freeman BD.

Am J Hematol. 2001 Jun;67(2):144-6.

36.

Successful electroconvulsive therapy given to a patient with von Willebrand's disease.

Sincoff RC, Giuffra LA, Blinder MA, Isenberg KE.

J ECT. 2000 Mar;16(1):68-70. No abstract available.

PMID:
10735334
37.

Donor-derived acute promyelocytic leukemia in a liver-transplant recipient.

Bodó I, Peters M, Radich JP, Hess J, Blinder M, Watson MS, Van Rheeden R, Natarajan S, Lowell JA, Brown R, DiPersio J, Adkins D.

N Engl J Med. 1999 Sep 9;341(11):807-13. No abstract available.

38.

Acute promyelocytic leukemia with additional chromosomal abnormalities and absence of Auer rods.

Kaleem Z, Watson MS, Zutter MM, Blinder MA, Hess JL.

Am J Clin Pathol. 1999 Jul;112(1):113-8.

PMID:
10396293
39.

Allosteric effects of a monoclonal antibody against thrombin exosite II

Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM.

Biochemistry. 1999 Feb 23;38(8):2610. No abstract available.

PMID:
10029715
40.

HPLC detection of fetal blood in meconium: improved sensitivity compared with qualitative methods.

Chen D, Wilhite TR, Smith CH, Blinder MA, Landt M.

Clin Chem. 1998 Nov;44(11):2277-80.

41.

Allosteric effects of a monoclonal antibody against thrombin exosite II.

Colwell NS, Blinder MA, Tsiang M, Gibbs CS, Bock PE, Tollefsen DM.

Biochemistry. 1998 Oct 27;37(43):15057-65.

PMID:
9790668
42.

Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations.

Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG.

Clin Chem. 1998 Jan;44(1):45-51.

43.

Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder.

Colwell NS, Tollefsen DM, Blinder MA.

Br J Haematol. 1997 Apr;97(1):219-26.

PMID:
9136969
44.

Multimodality therapy of an acquired factor V inhibitor.

Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA.

Am J Hematol. 1996 Apr;51(4):315-8.

45.

Gender differences in income for psychiatrists.

Blinder M.

Am J Psychiatry. 1995 Mar;152(3):480. No abstract available.

PMID:
7864293
46.

Role of lysine 173 in heparin binding to heparin cofactor II.

Whinna HC, Blinder MA, Szewczyk M, Tollefsen DM, Church FC.

J Biol Chem. 1991 May 5;266(13):8129-35.

47.

Complete nucleotide sequence of the gene for human heparin cofactor II and mapping to chromosomal band 22q11.

Herzog R, Lutz S, Blin N, Marasa JC, Blinder MA, Tollefsen DM.

Biochemistry. 1991 Feb 5;30(5):1350-7.

PMID:
1671335
48.
50.

Oxygen desaturation and changes in breathing pattern in patients undergoing colonoscopy and gastroscopy.

Barkin JS, Krieger B, Blinder M, Bosch-Blinder L, Goldberg RI, Phillips RS.

Gastrointest Endosc. 1989 Nov-Dec;35(6):526-30.

PMID:
2599296

Supplemental Content

Loading ...
Support Center